Clinical Trial Update: Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• ACI-24 (ACI-24)

Snippet

Sponsor: AC Immune SA | Conditions: Down Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2021-09-21